➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,585,868

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,585,868 protect, and when does it expire?

Patent 9,585,868 protects MYTESI and is included in one NDA.

This patent has twenty-six patent family members in twenty countries.

Summary for Patent: 9,585,868
Title:Methods and compositions for treating HIV-associated diarrhea
Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Inventor(s): Forbes; William (Raleigh, NC), Bortey; Enoch (Chapel Hill, NC), King; Steven (Moss Beach, CA), Chaturvedi; Pravin (Andover, MA)
Assignee: NAPO PHARMACEUTICALS, INC. (San Francisco, CA)
Application Number:14/597,740
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,585,868

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ⤷  Try it Free ⤷  Try it Free SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,585,868

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011320155 ⤷  Try it Free
Brazil 112013010774 ⤷  Try it Free
Canada 2816416 ⤷  Try it Free
China 103370101 ⤷  Try it Free
China 107595836 ⤷  Try it Free
Colombia 6771411 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.